Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: Recently published papers: Bugs, fluids, obesity and food. | Critical Care June 2004 Vol 8 No 3 Hall and Williams Commentary Recently published papers Bugs fluids obesity and food Neil Hall1 and Gareth Williams2 Specialist Registrar in Anaesthesia University Hospitals of Leicester Leicester UK 2Consultant in Anaesthesia and Critical Care University Hospitals of Leicester Leicester UK Corresponding author Gareth Williams garethdavidwilliams@ Published online 6 May 2004 This article is online at http content 8Z3 148 2004 BioMed Central Ltd Critical Care 2004 8 148-150 DOI cc2873 Infection and sepsis continue to dominate the critical care literature and in particular a condensation of evidence-based practice in this area from the Surviving Sepsis Campaign was published in March. Choosing the right resuscitation fluid in the right clinical setting remains contentious and why don t we include body mass index in severity of illness scoring Nosocomial infection In a report 1 and accompanying editorial 2 the March issue of Intensive Care Medicine examined therapy for ventilator-associated pneumonia VAP caused by Grampositive organisms. Methicillin-resistant Staphylococcus aureus MRSA in VAP accounts for 50 of all cases due to S. aureus which is the micro-organism most commonly responsible for nosocomial pneumonia with mortality ranging from 14 to 47 3 . Kollef and coworkers 1 compared linezolid with vancomycin therapy for MRSA VAP. In their retrospective analysis of two randomized double-blind studies 544 patients with suspected Gram-positive VAP including 264 with proven Gram-positive VAP and 91 with MRSA were treated with linezolid 600 mg or vancomycin 1 g every 12 hours for 7-21 days both combined with aztreonam a monobactam specific to Gram-negative organisms . Clinical cure rates assessed 12-28 days after therapy significantly favoured the linezolid group among Gram-positive and MRSA patients with clinical cure odds ratios of for Gram-positive VAP and for MRSA VAP. Linezolid was an .
